RE: MAKING PROGRESS10 Nov 2025 16:27
No one can accurately know profit margins or commercial terms at this stage, and JustHereForFleecing suggesting someone call the manufacturer to confirm costs is ludicrous and simply not even possible for sensitive commercial terms and it tells you how dangerous such comments are, nor does he know the cost element of these processes like his message is trying to imply.
The share price will move primarily based on clinical trial progress and news flow. If trials continue successfully, interest and the share price are likely to rise. If trials hit setbacks, the opposite may occur.
Commercial terms will remain unknown until agreements with major pharma partners are made. Regardless, shareholders stand to benefit if successful partnerships materialise. If not, dilution will likely continue.
Estonia is unlikely to fund the trials alone nor would you want it to as it will not allow the pace required. Anyone suggesting otherwise is naive and that’s IF it progresses at all.
In short, making statements of fact on speculative items that cannot be known at this stage is unproductive; the key drivers are trial results and tangible news updates not the utterly nonsensical suggestion of traders placing “A” trades to manipulate the share price for a few percent 🤡🤯
Both the rampers and those attempting to talk the stock down on a board like this are missing the point.
For a long-term holder who believes the ultimate outcome is a buyout, daily share price fluctuations are largely irrelevant. Short-term noise should not factor into the investment decisions.